|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671) |
Vir: |
|
|
|
List of services to meet your request
Contains list of services for current record
|
|
|
© 2024 SFX by Ex Libris Inc. | Cookie Policy
CrossRef Omogočeno
|